Previous close | 0.2000 |
Open | 0.2000 |
Bid | 0.0000 |
Ask | 0.3000 |
Strike | 1.50 |
Expiry date | 2024-05-17 |
Day's range | 0.2000 - 0.2000 |
Contract range | N/A |
Volume | |
Open interest | 1.51k |
Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2024, on Thursday, May 9, 2024, prior to the open of financial markets.
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 10 newly-hired employees options to purchase an aggregate of 41,000 shares of Akebia's common stock on April 30, 2024, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
With the business potentially at an important milestone, we thought we'd take a closer look at Akebia Therapeutics...